We are live on ! Find out more
AUTL

Autolus Therapeutics
AUTL

48 hedge funds and large institutions have $113M invested in Autolus Therapeutics in 2020 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 17 increasing their positions, 16 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 4

4% more funds holding

Funds holding: 46 → 48 (+2)

6% more repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 16

0.4% more ownership

Funds ownership: 23.71% → 24.11% (+0.4%)

21% less capital invested

Capital invested by funds: $142M → $113M (-$29M)

Holders
48
Holders Change
+2
Holders Change %
+4.35%
% of All Funds
0.85%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
17
Reduced
16
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BBA
Baker Bros. Advisors
New York
+$3.42M
2
EP
Eversept Partners
New York
+$1.65M
3
Schroder Investment Management Group
Schroder Investment Management Group
United Kingdom
+$1.14M
4
Morgan Stanley
Morgan Stanley
New York
+$997K
5
JP Morgan Chase
JP Morgan Chase
New York
+$806K

Top Sellers

Rank Fund Capital Flow
1
AG
Artal Group
Luxembourg
-$3.32M
2
GIM
Granahan Investment Management
Massachusetts
-$1.37M
3
Millennium Management
Millennium Management
New York
-$1.25M
4
Two Sigma Investments
Two Sigma Investments
New York
-$386K
5
WMSA
Weiss Multi-Strategy Advisers
New York
-$339K
Name Holding Trade Value Shares
Change 		Change in
Stake
WMSA
26
Weiss Multi-Strategy Advisers
New York
$166K -$339K -31,785 -63%
Geode Capital Management
27
Geode Capital Management
Massachusetts
$141K -$44.3K -4,160 -21%
BCM
28
Burrage Capital Management
Massachusetts
$134K – – –
Goldman Sachs
29
Goldman Sachs
New York
$129K -$141K -13,189 -48%
AG
30
Aperio Group
California
$111K +$11.2K +1,047 +9%
Legal & General Group
31
Legal & General Group
United Kingdom
$97K +$23.8K +2,231 +26%
UBS Group
32
UBS Group
Switzerland
$50K +$24.4K +2,285 +70%
Osaic Holdings
33
Osaic Holdings
Arizona
$46K +$1.07K +100 +2%
APA
34
American Portfolios Advisors
New York
$42.5K +$50.6K +4,750 New
TRCT
35
Tower Research Capital (TRC)
New York
$14K -$38.3K -3,591 -69%
RE
36
RBC Europe
United Kingdom
$12.5K +$14.9K +1,400 New
Citigroup
37
Citigroup
New York
$9K -$14.7K -1,376 -58%
CFGS
38
Concourse Financial Group Securities
Alabama
$9K -$5.33K -500 -33%
PCM
39
Penserra Capital Management
California
$7K +$5.45K +511 +180%
Bank of America
40
Bank of America
North Carolina
$5K -$302K -28,374 -98%
US Bancorp
41
US Bancorp
Minnesota
$5K -$4.59K -431 -44%
LC
42
Lindbrook Capital
California
$5K +$1.19K +112 +23%
PA
43
Parallel Advisors
California
$2K +$2.44K +229 New
ED
44
Exane Derivatives
France
$1.61K – – –
Daiwa Securities Group
45
Daiwa Securities Group
Japan
$1K -$1K -94 -56%
Barclays
46
Barclays
United Kingdom
$1K +$1.07K +100 +208%
Royal Bank of Canada
47
Royal Bank of Canada
Ontario, Canada
$1K +$1.18K +111 +3,700%
AG
48
Artal Group
Luxembourg
– -$3.32M -285,000 Closed
Two Sigma Investments
49
Two Sigma Investments
New York
– -$386K -33,177 Closed
TI
50
Trexquant Investment
Connecticut
– -$217K -18,646 Closed
1
2
3

AUTL Hedge Fund Activity: Q4 2020 in Review

48 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Autolus Therapeutics (AUTL) for Q4 2020, worth a combined $113M — down 21% from $142M a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new AUTL positions and 4 closed out — a net gain of 2 holders — while 17 added to existing stakes and 16 trimmed.

The largest buyer was Baker Bros. Advisors, adding an estimated $3.42M. The largest seller was Artal Group, exiting entirely with an estimated $3.32M sold.

  • 48 institutional investors held Autolus Therapeutics (AUTL) as of Q4 2020, up from 46 in Q3 2020.
  • Funds reported $113M of Autolus Therapeutics stock for Q4 2020, down 21% quarter-over-quarter.
  • 6 funds opened new Autolus Therapeutics positions in Q4 2020 and 4 closed out, a net change of +2 holders.
  • The largest Autolus Therapeutics buyer in Q4 2020 was Baker Bros. Advisors, an estimated $3.42M added.
  • The largest Autolus Therapeutics seller in Q4 2020 was Artal Group, an estimated $3.32M sold.

Based on aggregated 13F filings for Q4 2020.